Aspen forecasts strong 2027 growth on obesity drugs
Aspen Pharmacare forecast strong double-digit earnings growth for fiscal 2027. The South African drugmaker relies on a manufacturing recovery and generic weight-loss drug rollouts.
Xurve View
Insights:
Xurve View
ASPEN PHARMACARE HOLDINGS LT forecast fiscal 2027 normalised EBITDA of at least 9 billion rand ($561M), driven by manufacturing recovery and generic weight-loss drug rollouts. The South African drugmaker reported earnings on Wednesday following a fiscal year ended June 30. The group anticipates net interest savings of 1.2 billion rand to power double-digit headline earnings growth.
